Kerrisdale Advisers LLC Acquires Shares of 42,000 Zoetis Inc. $ZTS

Kerrisdale Advisers LLC acquired a new position in shares of Zoetis Inc. (NYSE:ZTS) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 42,000 shares of the company’s stock, valued at approximately $3,018,000. Zoetis accounts for 0.8% of Kerrisdale Advisers LLC’s holdings, making the stock its 27th largest holding.

Other institutional investors also recently modified their holdings of the company. Headlands Technologies LLC acquired a new position in shares of Zoetis in the second quarter valued at about $3,960,000. Quantitative Investment Management LLC acquired a new stake in Zoetis in the 2nd quarter worth about $3,242,000. Moore Capital Management LP acquired a new stake in Zoetis in the 2nd quarter worth about $14,570,000. Sigma Planning Corp boosted its holdings in Zoetis by 32.7% in the 2nd quarter. Sigma Planning Corp now owns 12,694 shares of the company’s stock valued at $912,000 after purchasing an additional 3,131 shares during the period. Finally, Two Sigma Securities LLC acquired a new position in shares of Zoetis during the 2nd quarter worth approximately $3,049,000. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of Zoetis stock opened at $77.45 on Monday. The company has a 50 day moving average of $75.57 and a 200-day moving average of $95.40. Zoetis Inc. has a 1-year low of $71.00 and a 1-year high of $156.49. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87. The company has a market cap of $32.00 billion, a PE ratio of 12.76, a price-to-earnings-growth ratio of 1.80 and a beta of 0.73.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.85 by $0.02. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The business had revenue of $2.47 billion for the quarter, compared to analysts’ expectations of $2.50 billion. During the same period last year, the firm posted $1.76 earnings per share. The firm’s quarterly revenue was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, equities research analysts forecast that Zoetis Inc. will post 6.2 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the stock. Argus reaffirmed a “hold” rating on shares of Zoetis in a report on Wednesday, May 27th. Weiss Ratings downgraded Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, June 12th. TD Cowen lowered their price objective on Zoetis from $104.00 to $94.00 and set a “buy” rating on the stock in a research note on Tuesday, August 25th. Morgan Stanley set a $85.00 price objective on Zoetis in a report on Friday, August 7th. Finally, Citigroup cut their target price on Zoetis from $112.00 to $96.00 and set a “buy” rating for the company in a research report on Tuesday, August 11th. Eight analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Zoetis has an average rating of “Hold” and a consensus target price of $107.43.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.